Technology III
iPSC Extracelluar Vesicles, EVs Purification Platform
Rapid Differentiation of Human iPSCs into Mature Hepatocytes and Large-Scale iPSC-EVs Production for Clinical Applications – Patent and Application.
We have developed an innovative method for rapidly guiding the differentiation of human induced pluripotent stem cells (iPSCs) into mature hepatocytes, offering a promising approach for liver disease treatment. This breakthrough technology enhances the efficiency and consistency of hepatocyte generation, providing a valuable tool for regenerative medicine, drug screening, and liver disease therapy. In addition, we have established a large-scale iPSC-derived EVs production platform optimized for clinical applications. iPSC-EVs are enriched with regenerative factors, making them highly effective in promoting cell repair, modulating inflammation, and enhancing tissue regeneration. Our proprietary purification and lyophilization processes ensure high-purity, stable, and bioactive exosome products suitable for various therapeutic applications.
This pioneering technology, titled "Methods for Producing Mature Hepatocytes," has been granted patents in Taiwan (Patent No. I449789) and the United States (Patent No. US 9732323), reinforcing its potential applications in hepatocyte transplantation, liver regeneration, and therapeutic development.
Combined with our expertise in iPSC-EVs production, we are advancing next-generation regenerative medicine solutions for unmet clinical needs.